Gastric cancer is one of the most frequent cancers in the world, for both men and women. Gastric cancer is the fourth most frequent cancer and is the second leading cause of cancer-related death worldwide. Nearly two-thirds of stomach cancers occur in developing countries. Despite innovations in treatment modalities, gastric cancer still remains a mortal disease. Gastric cancer is more frequent in the Eastern population and in Turkey than in the European population. It is the second leading cause of cancer death in men, and the third leading cause in women in Turkey. Unfortunately, diagnostic and prognostic markers are insufficient for this mortal and frequent tumor.

Epigenetic silencing of tumor suppressor genes is a hallmark in human cancers affecting multiple cellular pathways, such as cell signaling, adhesion and invasion, cell cycle, angiogenesis, DNA repair, and apoptosis. Epigenetic alterations contribute significantly to the development and progression of gastric cancer. Ubiquitin-like, containing PHD and RING finger domains 1 (UHRF1) is a newly discovered gene reported to have a function in maintaining DNA methylation by helping recruit DNA methyltransferase 1 (DNMT1) to hemimethylated DNA. UHRF1 is a putative oncogenic factor and is overexpressed in numerous cancers. There is insufficient data on the role of UHRF-1 in gastric carcinoma in the literature.

P53 is a well-known tumor suppressor gene and many human cancers are found to have a mutant p53 gene. In gastric carcinomas, p53 expression frequency has been reported to vary from 25% to 60%. Its prognostic role in gastric cancer has remained controversial.

In this study, p53 and UHRF-1 expression were investigated in gastric carcinoma and a control group. We aimed to investigate the diagnostic and prognostic value of these parameters for gastric carcinoma.
From 2008 to 2012, a total of 64 gastric cancer patients as a “study group” and 23 patients with gastritis as a “control group” were admitted. Their formalin-fixed, paraffin-embedded tissue samples were obtained from the files of the Pathology Department. For p53 MoAb, a mouse anti-human antibody, clone DO-7 (Dako, Glostrup, Denmark, Labvision Laboratories) and for UHRF-1 polyclonal rabbit, clone bs-6427R (Woburn, Massachusetts, USA, Bioss Laboratories were used for immunohistochemistry. Immunohistochemically, the avidin–biotin peroxidase complex technique was employed. 3-Amino-9-ethyl-carbazole (AEC) was used as the chromogen and Mayer’s hematoxylin was used for counterstaining. Negative controls were prepared by replacing the primary antibodies with normal mouse serum. Positive controls for UHRF-1 were prepared from breast carcinoma and colorectal carcinoma for p53. The p53 and UHRF-1 positive cases were semiquantitatively categorized. A staining of more than 5% of tumor cells was accepted as positive expression. The percentage of positive cells was divided into 5 grades (percentage cores): <5%, 0; 5%–25%, 1; 26%–50%, 2; 51%–75%, 3; and >75%, 4. Gastric cancer patients’ clinical data were obtained from hospital files.

Staging and grading were referred to the 7th edition of American Joint Committee on Cancer (AJCC) tumour-node metastasis (TNM) staging and classification for carcinoma of the stomach (2010). All patients underwent surgery/biopsy and postoperative treatment at the same hospital. Fifty-eight patients (91%) underwent surgery and six patients (9%) underwent only diagnostic biopsy and were admitted as inoperable. The surgical technique in this group was as follows: 28 (48%) patients subtotal gastrectomy, 28 (48%) patients total gastrectomy, and 2 (4%) patients palliative passage surgery. Thirty-nine (61%) patients were treated with surgery plus adjuvant chemo-radiotherapy. As a chemotherapy regimen, 5-fluorouracil and folinic acid were used for adjuvant treatment and docetecxal–cisplatin and 5-fluorouracil (DCF) were used for metastatic disease.

Statistical analysis of clinicopathological parameters was done with frequency analysis, Chi-square test, or Fisher’s exact test using a significance level of <0.05. The survival rates of the patients were estimated by the Kaplan–Meier method, and Cox regression analysis was used for all prognostic parameters. The SPSS 14.0 program (Chicago, IL, USA) for Windows was used for statistical analyses. A written informed consent was obtained from each subject and the study protocol was approved by the Human Ethics Committee of our university.

RESULTS

The study was performed on 64 patients (study group) with primary gastric carcinoma and 23 patients (control group) with gastritis. Forty-nine patients (77%) were male and 15 (23%) were female. The median age was 63 years (18–83 years). All of the patients had adenocarcinoma and seven (11%) of them had signet ring cell morphology. According to morphologic classification, 38 (59%) patients were diagnosed intestinal type and 26 (41%) patients were diffuse type. Perineural invasion (PNI) was positive in 29 patients (56%), lymphovascular invasion (LVI) was positive in 36 (68%) patients, and extracapsular involvement was positive in 22 (41%) patients. The stages of disease were: Two patients (3%) stage I, 13 (13%) patients stage II, 37 (58%) patients stage III, and 12 (19%) patients stage IV. The histopathological grades were 10 (16%) patients grade I, 19 (31%) patients grade II, 28 (47%) patients grade III, and 4 (6%) patients grade IV. Sixteen (25%) patients had at least one comorbid disease.

UHRF-1 was positive in 15 (23%) patients with gastric cancer and in five (21.7%) patients with gastritis ($P = 0.559$) [Figures 1 and 2]. UHRF-1 expression level in gastric cancer is more powerful than in gastritis ($P = 0.046$) [Table 1]. p53 was positive in 37 (61%) patients with gastric cancer [Figure 3] and in only one patient with gastritis ($P < 0.001$).

There was no correlation between p53 positivity and lymph node involvement, LV and PN invasion, stage or survival ($P > 0.05$). The p53 positivity was more common in metastatic patients than in nonmetastatic patients (89% vs 56%) but the difference was not statistically significant ($P = 0.061$). UHRF-1 positivity was more frequent in intestinal type (32% vs 11%), but the difference was not statistically significant ($P = 0.057$). Table 2 shows the
relationship with p53, UHRF-1 and LVI, PNI, lymph node, stage, histopathologic type, and metastasis status.

The median follow-up of gastric cancer patients was 12 months (1–110). The median survival was 20 months and, the 2 years overall survival rate was 47% in all gastric cancer patients. According to morphologic subtype, the 2 years overall survival rate and the median survival of patients with intestinal type were 59% and 22 months; the 2 years overall survival rate and the median survival of patients with diffuse type were 41% and 11 months, respectively ($P = 0.116$).

For positive p53 expression 2 years overall survival rate was 30%, whereas for negative expression it was 55% ($P = 0.084$).

Also, for positive UHRF-1 expression 2 years overall survival rate was 53%, whereas for negative expression it was 45% ($P = 0.132$). There was no correlation between survival and both UHRF-1 and p53. Table 3 demonstrates the survival rates according to p53 and UHRF-1.

### DISCUSSION

Despite advances in treatment, gastric cancer still has a high mortality.$^2$ The curative resection, depth of invasion, lymph node metastasis, HER2 status, stage, and carcinoembryonic antigen (CEA) level are important prognostic factors for gastric cancer.$^{2,18,19}$

Epigenetic modifications play a central role in gastric carcinogenesis.$^{20-22}$ UHRF-1, as an epigenetic regulator, has been shown to be overexpressed and to coordinate tumor suppressor gene silencing in several cancers.$^7$ UHRF-1 has been suggested to be an important biomarker to discriminate between cervical high-grade and low-grade cancer lesions.$^{23}$ Another study has highlighted the efficiency of UHRF-1 as a marker to differentially diagnose pancreatic adenocarcinoma, chronic pancreatitis, and normal pancreas.$^{24}$ UHRF-1 overexpression was also found in bladder cancer and the intensity of its overexpression appears to be related to the stage of the cancer suggesting that the presence of UHRF1 in urine sediment or surgical specimens could be a useful diagnostic marker and may improve the diagnosis of bladder cancer.$^{11}$ UHRF-1 overexpression has also been described in lung cancer cells, particularly in nonadenocarcinomas.$^{10}$ This alteration in UHRF-1 expression could be linked to the degree of lung cancer aggressiveness and was detectable in half of the patients in an early pathological stage. This suggests therefore that UHRF-1 could be a novel diagnostic tool for lung cancer.$^{10}$ On the other hand, according to Babbio and colleagues, UHRF-1 expression is correlated with a higher risk of fatality in prostate cancer patients.$^{25}$ According to Geng et al., the UHRF-1 DNA level in plasma is highly correlated with breast cancer and its stage, and may be a potential independent diagnostic and prognostic factor for breast cancer patients.$^{12}$

In our study, we compared patients with gastritis and with gastric cancer in order to look for the diagnostic value of UHRF-1 found to be a nondiagnostic marker. The patients with chronic active gastritis in the control group may have led to this negative result. It is known that stomach epithelium proliferation is frequent and its regeneration is continuous. UHRF-1 positivity in the control group may be secondary to the existence of active inflammation and proliferation, as in gastritis. Moreover, the success of the immunohistochemical test may vary according to the time that histopathologic slices are in the formaldehyde solution.
If we examined fresh tissue and used a real-time PCR method or monoclonal antibody for paraffin-embedded tissue, we may have obtained positive findings. There is very little information in the literature about the relationship between UHRF-1 and gastric cancer. Zhou et al. demonstrated that UHRF-1 was overexpressed in GC tissues and a high level of UHRF-1 expression predicted poor survival. Conversely, there was no correlation between UHRF-1 positivity and lymph node positivity, LVI positivity, PNI positivity, stage, and survival in our trial.

Mutations in the p53 gene belong to the most common genetic alterations in human cancer that have been implicated in tumorigenesis and tumor progression. In the literature, there are many studies about the importance of p53 in gastric cancer. Fondevila et al. demonstrated that p53 expression is an independent prognostic factor for both disease-free survival and overall survival in patients with curatively resected gastric cancer, and that p53 status may also influence response to chemotherapy. In gastric carcinomas, p53 expression frequency has been reported to vary from 25% to 60%. Maehara et al. highlighted that the expression of p53 was closely related to the potential for tumor advancement and a poorer postoperative prognosis for patients with gastric cancer. Deveci demonstrated that p53 positivity was a poor prognostic factor for more than five metastatic lymph nodes involved in gastric carcinoma patients. On the other hand, some studies did not support the prognostic value of p53 in gastric cancer. Hurlimann and Saraga, Fukunaga et al., and Gabbert et al. have found no relationship of p53 expression with liver metastasis or lymph node involvement. Gabbert et al. reported that p53 expression had no influence on survival, in either the lymph node-positive or -negative groups for gastric cancer. Correspondingly, in this study no correlation was found between p53 positivity and lymph node, LVI, PNI, stage, or survival. In fact, the p53 positivity was more common in metastatic patients than in nonmetastatic patients, but the difference was not statistically significant in this trial.

### Table 2: The relationship with P53, UHRF-1 and LVI, PNI, lymph node, stage, metastases status

| Variable               | N (%)     | P     | N (%)     | P     |
|------------------------|-----------|-------|-----------|-------|
|                         | P53 (−)   |       | P53 (+)   |       |
| LVI1                   |           |       |           |       |
| Negative               | 5 (24)    | 0.254 | 11 (28)   | 0.247 |
| Positive               | 11 (37)   |       | 6 (43)    |       |
| PNI2                   |           |       |           |       |
| Negative               | 12 (57)   | 0.145 | 15 (65)   | 0.205 |
| Positive               | 11 (38)   |       | 23 (79)   |       |
| Lymph node             |           |       |           |       |
| Negative               | 5 (21)    | 0.246 | 15 (31)   | 0.161 |
| Positive               | 12 (32)   |       | 2 (13)    |       |
| Stage                  |           |       |           |       |
| Stage 1-2              | 9 (60)    | 0.090 | 12 (80)   | 0.715 |
| Stage 3                | 13 (37)   |       | 27 (73)   |       |
| Stage 4                | 2 (18)    |       | 10 (83)   |       |
| Lauren classification   |           |       |           |       |
| Intestinal type        | 12 (33)   | 0.188 | 26 (68)   | 0.057 |
| Diffuse type           | 12 (48)   |       | 23 (89)   |       |
| Distant metastases     |           |       |           |       |
| No                     | 23 (96)   | 0.061 | 41 (84)   | 0.570 |
| Yes                    | 29 (78)   |       | 13 (87)   |       |

1LVI: Lymphovascular invasion, 2PNI: Perineural invasion

### Table 3: The survival rates according to p53 and UHRF-1

| p53/UHRF-1 | No. of patients | The 2 years OS rate (%) | Median survival (month) | P     |
|------------|-----------------|-------------------------|-------------------------|-------|
| P53        |                 |                         |                         |       |
| Negative   | 24              | 55                      | 26                      | 0.084 |
| Positive   | 37              | 30                      | 11                      |       |
| UHRF-1     |                 |                         |                         |       |
| Negative   | 49              | 45                      | 20                      | 0.132 |
| Positive   | 15              | 53                      | N/A                     |       |

1OS: Overall survival, 2N/A: Not available

Kakeji et al. Xiao et al., and Starzynska et al. reported a positive correlation between p53 expression and metastasis. Maehara et al. highlighted that the expression of p53 was closely related to the potential for tumor advancement and a poorer postoperative prognosis for patients with gastric cancer. Deveci demonstrated that p53 positivity was a poor prognostic factor for more than five metastatic lymph nodes involved in gastric carcinoma patients. On the other hand, some studies did not support the prognostic value of p53 in gastric cancer. Hurlimann and Saraga, Fukunaga et al., and Gabbert et al. have found no relationship of p53 expression with liver metastasis or lymph node involvement. Gabbert et al. reported that p53 expression had no influence on survival, in either the lymph node-positive or -negative groups for gastric cancer. Correspondingly, in this study no correlation was found between p53 positivity and lymph node, LVI, PNI, stage, or survival. In fact, the p53 positivity was more common in metastatic patients than in nonmetastatic patients, but the difference was not statistically significant in this trial.
CONCLUSION

This trial demonstrated that p53 might be helpful in differentiating gastric cancer and gastritis. Although UHRF1 expression positivity was similar in both gastric cancer and gastritis, expression level in gastric cancer was found to be more powerful. Both of them were not prognostic for gastric cancer in this study. The small patient number, the features of the control group, and the immunohistochemical method may be restrictive sides of this trial. It is necessary to perform an extensive study on this subject in the future.

REFERENCES

1. Stewart BW Kleihues P, Coates Alan S. Cancer Prevntation: A Global Perspective. JCO 2005;23:392-403.
2. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1998;1:125-33.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005:55:74-108.
4. Esteller M. Epigenetic gene silencing in cancer: The DNA hypermethylome. Hum Mol Genet 2007;16:RS10-9.
5. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005:55:74-108.
7. Kim JK, Estève PO, Jacobsen SE, Pradhan S. UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucelic Acids Res 2009;37:493-505.
8. Bronner C, Achour M, Arima Y, Chataigneau T, Saya H, Schini-Kerth VB. The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther 2007;115:419-34.
9. Unoki M, Brunet J, Mousli M. Drug discovery targeting epigenetic histone modifications, as a drug target in cancers and toxoplasmosis. Biochem Pharmacol 2009;78:1279-88.
10. Zhou L, Zhao X, Han Y, Lu Y, Shang Y, Liu C, et al. Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis. FASEB J 2013;27:4929-39.
11. Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993;67:589-93.
12. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
13. Xiao LJ, Zhao S, Zhao EH, Zheng X, Gou WF, Takano Y, et al. Clinicopathologic and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas. Oncol Lett 2013;6:1277-84.
14. D'Emic M, Deveci G, Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer 2007;10:112-6.
15. Fukunaga M, Monden T, Nakanishi H, Ohue M, Fukuda K, Tomita N, et al. Immunohistochemical study of p53 in gastric carcinoma. Am J Clin Pathol 1994;101:177-80.
16. Pinto-de-Sousa J, Silva F, David L, Leitão D, Seixas M, Pimenta A, et al. Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology 2004;44:323-31.
17. Gabbert HE, Müller W, Schneider A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6.
18. Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-9.
19. Kim J-P, Lee J-H, Kim S-J, Yu H-J, Yang H-K. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1998;1:125-33.
20. Kacan T, Akgül Babacan N, Kilicakp S, Metin Seker, Yucel B, Uncu T, et al. Prognostic factors in patients with non-metastatic gastric cancer. Cumhuriyet Med J 2013;35:326-311.
21. Gigeck CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, Smith MA. Epigenetic mechanisms in gastric cancer. Epigenomics 2012;4:279-94.
22. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: A review. Gastric Cancer 2005;8:86-94.
23. Lorenzato M, Caudroy S, Bromley S, Evrard G, Simon M, Durlach A, et al. Cell cycle and/or proliferation markers: What is the best method to discriminate cervical high-grade lesions? Hum Pathol 2005;36:1101-7.
24. Crgogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 2005;129:1454-63.
25. Babbio F, Pistore C, Curtis L, Castiglioni I, Kunderfranco P, Brino L, et al. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene 2012;31:4878-87.